Kornimate/medical-research-clean huggingface dataset:
clinical registry collecting real world evidence on wound care treatments

Conditions: Wounds and Injuries; Burns; Mohs Surgery; Diabetic Foot Ulcer Mixed; Venous Leg Ulcer; Non-healing Wound; Trauma Injury; Injury and Wounds; Degloving Injuries; Pressure Ulcers, Bedsores, Decubitus Ulcer

Summary: collect data on various wound/injuries treatments and their related wound healing process, in real life settings. over a 12-week period per wound treated. analyze the safety and efficacy of wound treatments, including advanced biological/synthetic grafts with designations of 361 hct/ps or 510(k) fda clearance and standard of care wound treatments.

this clinical registry is an observational study to collect prospective and retrospective data on subject health, wounds and wound care procedures from medical centers, including skilled nursing facilities, hospitals, outpatient clinics, home health and any other medical environment where wounds are treated. structured data including wound photos are to be collected at the point of care in the subject electronic case report form. the registry will enroll data of up to 5000 wounds in up to 50 wound care locations. the dataset includes all wound/injuries and ulcer types.

Eligibility criteria:
inclusion criteria: 1. subjects are 18 years of age or older. 2. subject has an ulcer (diabetic foot ulcer, venous stasis ulcer, etc.), injury (trauma, post -surgical, mohs treatment), burns injury, and acute/chronic wounds. 3. subject agrees to the use of his health data, including photos of his wound in analysis and publications. 4. subject/lar must be able to read and understand english and/or spanish. exclusion criteria: 1. subject/lar is unable to read and understand english or spanish.

Keywords: wound dfu - diabetic foot ulcer vlu - venous leg ulcer post surgical trauma chronic wound mohs - mohs micrographic surgery non-healing wound
picoplatin as second-line therapy for patients with small cell lung cancer

Conditions: Small Cell Lung Cancer

Summary: this is a phase ii research study that is designed for patients who have small cell lung cancer (sclc) that is no longer responding to treatment. patients will receive picoplatin, a new platinum-based agent that is currently under investigation, in 21-day cycles.

platinum drugs work by binding to dna and preventing the rapid cell division of tumors. however, many tumors demonstrate a resistance to platinum drugs. results from preclinical studies indicate that picoplatin (previously called amd473 or zd0473) may be able to overcome or partially overcome platinum resistance. more than 500 patients have received picoplatin in previous phase i or phase ii clinical trials.

Eligibility criteria:
main inclusion criteria: 1. diagnosis of small cell lung cancer. 2. patients must have had one prior chemotherapy regimen which must have included either cisplatin or carboplatin. \[additional eligibility criteria apply.\] exclusion criteria: * prior radiotherapy that included \> 30% of the bone marrow (i.e., the whole of the pelvis or half of the spine). * significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom. * significant heart disease. * uncontrolled, untreated, unstable, or symptomatic brain tumors or central nervous system disease. * grade 2+ peripheral neuropathy (a condition caused by damage to the nerves in the peripheral nervous system). \[additional exclusion criteria apply.\]

Keywords: small cell lung cancer resistant refractory platinum chemotherapy second-line relapse sensitive
performance of the water-enema computed tomography (we-ct)

Conditions: Colon Cancer

Summary: the we-ct is an innovative and easy practice imaging technique of colon tumors; it is based on the colon distension by a high volume of warm water and a multidetector ct acquisition after iv (intravenous) contrast, allowing image analysis including the wall thickness and enhancement, the pericolic adjacent spaces and the entire abdomen. the goal of the study is the evaluation of its performances for the diagnosis of colon tumors.


Eligibility criteria:
inclusion criteria: * written informed consent * we-tc indication for colon tumor suspicion * age \> 18 years exclusion criteria: * pregnancy * patients under 65 years old and for whom the only we-tc indication is familial antecedents of colon tumor, without clinical or para-clinical personal signs for this pathology * infected sigmoid diverticulosis * occlusive syndrome * anesthesia contraindications * anal incontinence * renal insufficiency (creatinine \> 150 micromol/l) * iode allergy * visceralgine contraindications * scania contraindications

Keywords: water-enema computed tomography colon tumor coloscopy suspicion of colon tumor coloscopy or surgery
bimatoprost/timolol versus travoprost/timolol

Conditions: Glaucoma

Summary: the purpose of this study is to compare 2 fixed combination medications in intraocular pressure lowering.

purpose: to compare the efficacy of bimatoprost/timolol (btfc) or travoprost/timolol (ttfc) fixed combinations on intraocular pressure (iop) reduction in an egyptian population. methods: patients with primary open angle glaucoma (poag) were randomized to receive either btfc or ttfc. iops were measured at baseline, 2 weeks, and 1, 2, 4, and 6 months. the primary outcome measures were the mean change in iop from baseline

Eligibility criteria:
inclusion criteria: * glaucoma exclusion criteria: * no other ocular diseases
the pathogenesis of terson syndrome and the role of csf tau / amyloid-ß 40 and 42 in patients with aneurysmatic subarachnoid hemorrhage

Conditions: Subarachnoid Hemorrhage; Terson Syndrome; CSF-proteines

Summary: prospective clinical study to investigate the pathogenesis of terson syndrome and the prognostic value of the csf-biomarkers tau-protein and amyloid-β 40 and 42 in patients with aneurysmatic subarachnoid hemorrhage. our two hypotheses are as follows: 1. the incidence of terson syndrome correlates with the initial intracranial opening pressure (measured with extra ventricular drain) 2. the csf-biomarkers correlate with the outcome assessed at discharge, 3-, 6- and 12-months postictally using glasgow-outcome-scale-extended (gose) and euro-qol-5 as well as with complications related to aneurysmatic subarachnoid hemorrhage such as cerebral vasospasm, delayed cerebral ischemia and re-bleed.

in this prospective clinical study the pathogenesis of terson syndrome and the prognostic value of the csf-biomarkers tau-proteine and amyloid-β 40 and 42 in patients with aneurysmatic subarachnoidal hemorrhage are investigated. intracranial opening pressure will be measured in patients requiring csf-diversion for acute hydrocephalus and correlated with the incidence of terson syndrome tested by an opthalmologic exam (group a: terson syndrome positive, group b: terson syndrome negative). csf samples from external ventricular drainages are obtained at day 0, 2 and 6 and concentration of tau-protein and amyloid-β 40 and 42 are determined and correlated to secondary outcome measures such as delayed cerebral ischemia, clinical vasospasm, re-bleed, necessity for surgical intervention secondary to raised intracranial pressure or csf-diversion. outcome in terms of glasgow-outcome-scale-extended and euro-qol-5 will be assessed at 3, 6 and 12 months. csf from patients undergoing diagnostic or therapeutic tapping of their internal ventricles for normal pressure hydrocephalus or shunt diagnostics serve as a reference for csf-biomarkers concentration in healthy individuals.

Eligibility criteria:
inclusion criteria: * older than 18 years * diagnosis of subarachnoid hemorrhage secondary to an intracranial aneurysm * aneurysmatic subarachnoid hemorrhage must be the principal diagnosis for hospitalization * an intracranial aneurysm must be confirmed by imaging (computed tomography, magnet resonance tomography or angiography) * patients requiring diagnostic/therapeutic tapping of their internal ventricles for csf-diversion (shunt) for normal pressure hydrocephalus or shunt diagnostics serve as a control group * informed consent exclusion criteria: * younger than 18 years * other diagnosis such as traumatic or perimesencephalic subarachnoid hemorrhage without an intracranial aneurysm

Keywords: subarachnoid hemorrhage terson syndrome csf-proteines phospho-tau beta-amyloid
smart device-based cardiac rehabilitation after myocardial intervention

Conditions: Myocardial Infarction

Summary: the aim of this study is to evaluate the influence of cardiac rehabilitation based on smart band use and telemonitoring on functional capacity change and risk factors control among patients hospitalized for acute myocardial infarction.


Eligibility criteria:
inclusion criteria: 1. signed informed consent with the study 2. men and women \>18 years of age 3. patients ≥1 and ≤6 months after type i myocardial infarction 4. physical inactivity before mi defined as the absence of moderate to vigorous exercise for at least 30 minutes 5 or more days a week exclusion criteria: 1. heart failure nyha iiib-iv 2. planned coronary revascularization 3. planned major surgery within the next 12 months 4. inability to walk for any reason 5. comorbidities that would preclude adherence to the rehabilitation program (e.g. arthrosis, active malignancy, major depression or other significant psychiatric disorder, cognitive impairment) - at the discretion of the physician 6. life expectancy less than 12 months 7. pregnancy 8. inability to operate the smart-watch

Keywords: myocardial infarction cardiac rehabilitation smart device remote monitoring telemonitoring low physical activity risk factors control
cranial cup use for correction of head shape deformities

Conditions: Dolichocephaly

Summary: the purpose of this descriptive study is to provide information on the feasibility of using the cranial cup, a new positioning device, in a small sample of prematurely born infants with elongated head shapes as a result of laying on their abdomens, during the convalescent phase of their hospitalizations.

the cranial cup is a non-invasive, non-restrictive, adjustable orthotic device that grows with the infant and maintains proper body alignment while promoting normal head shape development. while the cranial cup is not yet fda approved, it is considered a non-significant medical device and it has successfully corrected asymmetric positional head shape deformities in hundreds of healthy newborns less than 4 months of age cared for by the children's hospital boston outpatient plagiocephaly clinic. additionally preliminary analysis of a prospective randomized controlled trial currently underway suggests that the cranial cup may be useful in prevention of positional head shape deformity in a cohort of hospitalized infants of varying gestational ages. however, the cranial cup has never been used for correction of the most common form of positional head shape deformity in hospitalized premature infants; namely dolichocephaly. thus, the purpose of this descriptive study is to provide information on the feasibility of using the cranial cup in a small sample of prematurely born infants with dolichocephaly during the convalescent phase of their hospitalizations. information obtained from this descriptive study will be used to determine if a larger investigation using the cranial cup is warranted in this specific patient population.

Eligibility criteria:
inclusion criteria: * born at \< or equal to 35 weeks gestation * cleared for participation by healthcare team * estimated minimum length of stay \>14 days * weight \>1000 grams (at enrollment) * dolichocephalic head shape deformity exclusion criteria: * unable to maintain airway patency (anatomical problem) * craniofacial anomaly or scalp device, drain or shunt * craniosynostosis * severe parturitional head shape deformity
advance mpi 2: study of regadenoson versus adenoscan® in patients undergoing myocardial perfusion imaging (mpi)

Conditions: Coronary Artery Disease

Summary: adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. the investigational drug, regadenoson (cvt-3146) is a selective a2a adenosine receptor agonist, the receptor responsible for coronary vasodilation, and is being studied for potential use as a pharmacologic stress agent in myocardial perfusion imaging (mpi) studies. this study will compare the safety and efficacy of regadenoson to that of adenoscan in detecting reversible myocardial perfusion defects.

advance mpi 2 is a multi-national, double-blind, randomized, active-controlled, parallel group clinical trial to evaluate the safety and efficacy of regadenoson in spect mpi compared to that of the approved pharmacological stress agent, adenoscan. patients referred for a clinically indicated pharmacological stress mpi study will be eligible for enrollment. the trial is designed: (1) to compare the pharmacological stress spect images obtained with regadenoson to those obtained with adenoscan, and (2) to compare the safety and tolerability of the two stress agents.

Eligibility criteria:
inclusion criteria: * referred for a clinically indicated pharmacological stress spect myocardial perfusion imaging study exclusion criteria: * any condition precluding the safe administration of adenoscan for a spect myocardial perfusion imaging study * pregnant or breast-feeding, or (if pre-menopausal), not practicing acceptable method of birth control

Keywords: lexiscan regadenoson adenoscan® adenosine spect myocardial perfusion imaging reversible perfusion defect
minocycline hydrochloride in reducing chemotherapy-induced peripheral neuropathy and acute pain in patients with breast cancer undergoing treatment with paclitaxel

Conditions: Acute Pain; Breast Carcinoma; Peripheral Neuropathy

Summary: this randomized pilot trial studies how well minocycline hydrochloride works in reducing chemotherapy-induced peripheral neuropathy and acute pain in patients with breast cancer undergoing treatment with paclitaxel. drugs used in chemotherapy, such as paclitaxel, may cause damage to nerves that result in aches, pains, and tingling or numbness of fingers and toes. minocycline hydrochloride may help lessen nerve damage from paclitaxel and improve the quality of life in breast cancer patients.

primary objectives: i. to estimate whether minocycline hydrochloride (minocycline) can alleviate paclitaxel-induced peripheral neuropathy. ii. to estimate whether minocycline can alleviate paclitaxel acute pain syndrome (p-aps). iii. to examine the possible relative toxicities related to minocycline therapy in this study situation. outline: patients are randomized to 1 of 2 arms. arm i: patients receive minocycline hydrochloride orally (po) twice daily (bid) on days 1-7. treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. arm ii: patients receive a placebo po bid on days 1-7. treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. after completion of the study, patients are followed up every month for 6 months.

Eligibility criteria:
inclusion criteria: * ability to complete questionnaires by themselves or with assistance * planned paclitaxel at a dose of 80 mg/m2 iv given, in the adjuvant breast cancer (postoperative or neo-adjuvant) setting, every week for a planned course of 12 weeks without any other concurrent cytotoxic chemotherapy (trastuzumab and/or other antibody and/or small molecule treatment is allowed, except for parp inhibitors) * life expectancy \> 6 months * eastern cooperative oncology group (ecog) performance status 0 or 1 * negative pregnancy test (serum or urine) done =\< 7 days prior to registration, for women of childbearing potential only (determined per clinician discretion) exclusion criteria: * any of the following: * pregnant women * nursing women * men or women of childbearing potential who are unwilling to employ adequate contraception * previous diagnosis of diabetic neuropathy or peripheral neuropathy from any cause * history of allergic or other adverse reactions to minocycline * prior exposure to neurotoxic chemotherapy * diagnosis of fibromyalgia * current or planned use of methoxyflurane, oral contraceptives, isotretinoin, penicillin, or ergot alkaloids * history of allergic or other adverse reactions to tetracycline
music and premenstrual symptoms and quality of life

Conditions: MUSIC THERAPY; Premenstrual Syndrome

Summary: premenstrual syndrome is an important health problem affecting women of childbearing age. this study is a prospective, single-blinded randomized controlled trial. participants were randomized into music, and control groups. immediately post-intervention, the women in the experimental groups had significantly higher reduce premenstraul syndrome levels and increase a quality life.

premenstrual syndrome is an important health problem affecting women of childbearing age. this study aimed to show that music medicine can be used to reduce premenstrual syndrome levels and increase quality of life. this study is a prospective, single-blinded randomized controlled trial. the study was conducted between january and april 2021 with 97 women who are college students. participants consisted of women over 20 years of age and with have premenstraul snydrome. participants were randomized into music, and control groups. immediately post-intervention, the women in the experimental groups had a significantly higher reduce premenstraul syndrome levels and increase a quality life. each method (music and control group) is evaluated for the premenstrual syndrome scale and short form of the whoqol-bref.

Eligibility criteria:
inclusion criteria: * being between the ages of 18 and 30 * being able to speak and understand turkish, * having obtained a score of 45 and above from the pmss, * having regular menstruation (between 21-35 days), * completing the scale forms completely and reading and approving the voluntary consent form exclusion criteria: * having any gynecological disease (abnormal uterine bleeding, myoma, ovarian cysts, hormonal treatment, etc.), * having a chronic or physical disease (serious hearing and vision problems, vestibular disorders that may cause balance losses), * having any problem that prevents the person from communicating (not being able to speak turkish, having speaking disabilities, impaired hearing, understanding abilities), * undergoing a psychiatric treatment (pharmacotherapy or psychotherapy), * performing one of the pharmacological or non-pharmacological practices aimed at reducing the symptoms of premenstrual symptoms (oral contraceptive use, acupressure, homeopathy, acupuncture) and exercising regularly.

Keywords: premenstrual syndrome music medicine quality life midwife nurse
children, perennial allergic rhinitis (par), l-t growth

Conditions: Perennial Allergic Rhinitis

Summary: the purpose of this study is to compare the effect of rhinocort nasal spray with placebo on growth in children with perennial allergic rhinitis over 12 months.


Eligibility criteria:
inclusion criteria: * in the opinion of the investigator, is a candidate for treatment with nasal steroids based on a history of either a) inadequate control of symptoms with antihistamines, decongestants and/or immunotherapy, or b) prior successful treatment with nasal steroids. * a documented history of at least one year of perennial allergic rhinitis. * a positive response to a skin prick test for perennial allergens that must be present in the subject's environment. * height and weight within normal limits. exclusion criteria: * any disease which may affect growth * sexual development later than tanner stage i. * nasal candidiasis, rhinitis medicamentosa, acute or chronic sinusitis, influenza, upper respiratory tract infection or structural abnormalities of the nose (e.g., septal deviation, nasal polyps) symptomatic enough to cause significant nasal obstruction as judged by the investigator.

Keywords: allergic rhinitis perennial allergic rhinitis paediatric growth budesonide rhinocort aqua
laparoscopic assisted pull-through versus other surgical procedures for treatment of hirschsprung disease

Conditions: Hirschsprung Disease

Summary: to evaluate the outcomes of laparoscopic pull-through concerning constipation, incontinence and enterocolitis in comparison of other surgical procedures for treatment of hirschsprung disease.

hirschsprung,s disease (hd) is a relatively common cause of intestinal obstruction in the newborn\[1,2\], the main goal in the treatment of patients with hirschsprung,s disease is to resect the aganglionic segment and pull down the normo-ganglionic bowel\[3\]. with the introduction of minimally invasive surgery, classic pull-through techniques were modified and improved with laparoscopy, because of the obvious advantages of laparoscopic-assisted pull-through operations in form of reduced pain and improved cosmoses this approach has gained much popularity\[4,5\].

Eligibility criteria:
inclusion criteria: 1. age from 6months to 3 years. 2. both sexes. 3. classic and long segment hirshsprung. 4. total a ganglionic colon. 5. hirshsprung disease with leveling colostomy exclusion criteria: 1. patients \ 3 years. 2. short and ultra-short hirshsprung. 3. recurrent cases of hirshsprung. 4. other contraindication of laparoscopy
bacterial contamination: iodine vs saline irrigation in pediatric spine surgery

Conditions: Surgical Site Infection

Summary: this study will evaluate the safety of povidone-iodine irrigation in pediatric spinal patients by collecting pre- and post-operative safety labwork. furthermore, the efficacy of povidone-iodine and normal saline irrigation at reducing bacterial contamination of the surgical wound will be measured by collecting cultures before and after irrigation.

previous research has shown there is baseline bacterial contamination of surgical spinal wounds prior to closure. while this bacterial contamination may or may not lead to infection, recent adult studies demonstrated reduced infection rates by using povidone-iodine irrigation before closure. this study will determine the safety of using povidone-iodine irrigation in pediatric spinal patients and how effective it is at reducing bacterial contamination of the spinal surgical wound prior to closure, compared with normal saline. the investigators hypothesize povidone-iodine is both safe and effective. understanding techniques that reduce the local bacterial load in the wound prior to closure after spinal fusion will give data to support measures that will ultimately reduce the rate of postoperative infections.

Eligibility criteria:
inclusion criteria: 1. age 3 to 18 years on day of surgery 2. diagnosis of spinal deformity 3. undergoing elective posterior spine multi-level instrumentation surgery exclusion criteria: 1. documented renal failure 2. documented allergy to iodine or shellfish 3. previous spine fusion surgery 4. undergoing elective posterior spine single-level instrumentation surgery 5. undergoing anterior spine multi-level instrumentation surgery 6. current antibiotic use.

Keywords: scoliosis spine fusion 0.35% povidone-iodine